This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
March 3 - March 5
As the NK community remains determined as ever to prove the advantages of NK cells, the year of the ‘bounce back’ now feels within reach. Driven by expansion into autoimmune pipelines, Artiva’s $160M IPO marks a sizeable return of investment into this space. It is now business critical for NK developers to capitalize on the new momentum building and showcase clinically validated pipelines to investors to demonstrate the potential of NK therapies and bring long lasting benefit to patients in need.